Predictors of willingness to participate in window-of-opportunity breast trials

about

Evaluating the feasibility of performing window of opportunity trials in breast cancer.

P2860

Q35061474-66472362-4914-4C68-B874-33EF38D6D081

P2860

Predictors of willingness to participate in window-of-opportunity breast trials

Item

http://www.wikidata.org/entity/Q37210705

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predictors of willingness to participate in window-of-opportunity breast trials

@en

Predictors of willingness to participate in window-of-opportunity breast trials.

@nl

type

Item

label

Predictors of willingness to participate in window-of-opportunity breast trials

@en

Predictors of willingness to participate in window-of-opportunity breast trials.

@nl

prefLabel

Predictors of willingness to participate in window-of-opportunity breast trials

@en

Predictors of willingness to participate in window-of-opportunity breast trials.

@nl

P1476

Predictors of willingness to participate in window-of-opportunity breast trials

@en

P2093

Adrienne Faerber

http://www.w3.org/2001/XMLSchema#string

Howard H Bailey

http://www.w3.org/2001/XMLSchema#string

Jane A McElroy

http://www.w3.org/2001/XMLSchema#string

Kari B Wisinski

http://www.w3.org/2001/XMLSchema#string

Kyungmann Kim

http://www.w3.org/2001/XMLSchema#string

Stephanie Wagner

http://www.w3.org/2001/XMLSchema#string

Thomas C Havighurst

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

22. Diagnostic delays in breast cancer and impact on survival.

Breast cancer prevention trials using retinoids.

Willingness to participate in clinical trials among African Americans and whites previously exposed to clinical research.

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Breast-tissue sampling for risk assessment and prevention.

Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation

Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.

Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status.

Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

P304

107-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3121/CMR.2013.1136

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236197236

http://www.w3.org/2001/XMLSchema#string

P698

23580787

http://www.w3.org/2001/XMLSchema#string

P932

3788556

http://www.w3.org/2001/XMLSchema#string

Predictors of willingness to participate in window-of-opportunity breast trials

about

P2860

P2860

Predictors of willingness to participate in window-of-opportunity breast trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932